The results of two different methods of CNS prophylaxis during consolidation were evaluated among fifty one acute lymphoblastic leukemia patients (ALL) treated in 1980-1991 in the Department of Hematology in Katowice. In group I (n = 28) methotrexate (Mtx) was used intrathecally (it) in 6 doses of 18 mg, in group II high dose cytosine arabinoside (Hi AraC)--3g/m2 intravenously (4x) was used with CNS rtg--therapy (18-24Gy). In both groups frequency of CNS relapses was similar 17.
View Article and Find Full Text PDFFifty six adult acute nonlymphoblastic leukemia patients were randomised in 1993 year according to Polish Acute Leukemia Group (PALG) into prospective, cooperative trial with the same prognostic factors distribution. The results of induction treatment using idarubicin on days 1, 3, 5 plus arabinoside cytosine 1-7/10 plus etoposide 1-5 (ICE7/10) vs. daunorubicin on days 1-3 plus Ara-C 1-7/10 with additional HD Ara-C in case of not sufficient cytoreduction in 6th day's bone marrow biopsy (3+7/+/-HD) and etoposide in M4-5 subtype are comparable (63 vs.
View Article and Find Full Text PDFFive hundred twenty patients with de novo non-lymphocytic leukemia (ANLL) were classified according to morphocytochemical FAB criteria and then immunophenotyped using a set of 20 monoclonal antibodies (MoAb) of VI series. It was demonstrated that immunophenotyping increased the proportion of properly classified leukemias from 87% after morphocytochemical evaluation up to 97.5%.
View Article and Find Full Text PDFHaematologia (Budap)
April 1993
In the group of 75 ALL patients treated between 1980 and 1989, two women (ages 25 and 17, both FAB-L2 and CALLA +, after 56 and 34 months of continuous CR, respectively) were found to have a relapse manifested as a local infiltration of skin, with involvement of the adjacent lymph nodes in one patient. The leukaemic character of the skin infiltration was confirmed by skin needle aspiration and tissue biopsy expressing CD10 and CD24. Both patients were given intensified systemic chemotherapy and local X-ray irradiation.
View Article and Find Full Text PDFActa Haematol Pol
October 1992
Mitoxantrone is a new anthracenodione derivative with a high antineoplastic activity in proliferative diseases of the haemopoietic system. In the Institute of Haematology in Warsaw and in the Department of Haematology, Silesian Medical Academy in Katowice this agent was used in combination with cytarabine in 49 cases of acute leukaemia (35 with acute myeloid leukaemia and 14 with acute lymphoblastic leukaemia). The preparations used were Mitoxantrone (POLFA Works in Jelenia Góra) and Novantrone (Lederle).
View Article and Find Full Text PDF